Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | $87.37M |
| Net Income (Most Recent Fiscal Year) | $-144.74M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.37 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -55.69% |
| Return on Assets (Trailing 12 Months) | -50.73% |
| Current Ratio (Most Recent Fiscal Quarter) | 17.85 |
| Quick Ratio (Most Recent Fiscal Quarter) | 17.85 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.78 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.37 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 111.19M |
| Free Float | 99.07M |
| Market Capitalization | $1.47B |
| Average Volume (Last 20 Days) | 1.05M |
| Beta (Past 60 Months) | -0.16 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.84% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |